Skolkovo presents the development and difficulties of its biomed startups
20 June 2022
At the moment, there are more than 3,000 startups in Skolkovo, 700 of them in the environmental and medical industries. In the next 3-5 years, startups and the industry will focus on import substitution, reverse engineering and rebuilding disrupted logistics chains, and in the next 5-7 years, on creating technological foundations that will help ensure leadership in the future.
The Ministry of Health announces that about 80% of VED-listed medicines can be produced in Russia
20 June 2022
The Russian pharmaceutical industry is capable of producing about 80% of the items from the list of vital and essential drugs (VED). This was stated by Viktor Fisenko, First Deputy Minister of Health of the Russian Federation, at Drug Safety forum held as part of the St. Petersburg International Economic Forum (SPIEF).
Skolkovo presents the development and difficulties of its biomed startups
20 June 2022
At the moment, there are more than 3,000 startups in Skolkovo, 700 of them in the environmental and medical industries. In the next 3-5 years, startups and the industry will focus on import substitution, reverse engineering and rebuilding disrupted logistics chains, and in the next 5-7 years, on creating technological foundations that will help ensure leadership in the future. This was told by Kirill Kayem, Vice President for Innovation of the Skolkovo Foundation, at the session “Entrepreneurship in Healthcare in the Era of Change”, held as part of the 25th St. Petersburg International Economic Forum.
Murashko describes some measures aimed at counteracting possible new pandemics
17 June 2022
International cooperation between Russia and other countries in the production of vaccines continues. During the pandemic, several cardinal changes took place: a law on biological safety appeared, and several countries adopted the same legal regulation at the same time, Mikhail Murashko, the Minister of Health of the Russian Federation, said during the session “Vaccine Production: International Cooperation in the Name of Health” at the 25th St. Petersburg International Economic Forum.
Onshoring and global health – has the pandemic sent globalisation into reverse?
17 June 2022
The pandemic has been a game-changer for the pharmaceutical industry, sending the seemingly inexorable globalisation trends into reverse, with Big Pharma increasingly seeking more domestic supply chain options. Here, Karen Winterhalter of Onyx Health shares her expert insights on the impact of this emerging trend on the industry.
Tumor structural genetic signatures offer blueprint for cancer precision medicine
16 June 2022
Most research on cancer therapies focuses on single genetic mutations. But chromosomal instability, which leads to losses, gains and rearrangements of DNA, represents another common feature of cancer that’s been less studied.
Unlocking the Potential of Cell and Gene Therapies
16 June 2022
As the cell and gene therapy market continues to emerge from relative infancy, the innovative products entering the pipeline today offer promise and hope for diseases with high unmet medical needs—from various forms of cancer to central nervous system disorders and cardiovascular diseases.
An Integrated Approach to Developing Next-Generation Genomic Medicines
15 June 2022
Few dispute that the rapid development and approval of two mRNA vaccines against COVID-19 was an unmitigated success, or that the evolving field of gene therapy has delivered multiple successful treatments for a range of rare diseases. Still, genomic medicines is a field that’s ripe for further innovation, in areas ranging from the development of improved delivery vehicles to the streamlining of manufacturing.
Into the thick of it: Scientists discover mechanism behind certain heart disorders
14 June 2022
Scientists have uncovered a mechanism behind the thickening of the heart muscle wall—a process tied to higher risk of irregular heart rhythms and heart failure.
The Ministry of Health of Russia issued registration certificate to Rapharma’s Oliramus drug
14 June 2022
Rapharma received registration certificate ËÏ-¹(000744)-(ÐÃ-RU) for its drug Oliramus drug (INN Everolimus) from the Ministry of Health of the Russian Federation. The drug will be available to patients in three dosages (2.5 mg, 5 mg, and 10 mg). This is reported on the company’s official website.
Russia starts phase 3 trials of its first domestic HPV vaccine
01 July 2022
Free medicines provision was suggested for patients with ischemia
01 July 2022
30 June 2022
A project on remote sale of prescription drugs has been presented
30 June 2022